The estimated Net Worth of Neil 122 62 507 Ryding is at least $1.16 Milion dollars as of 7 June 2018. Neil Ryding owns over 183 units of Haemonetics stock worth over $1,103,124 and over the last 9 years Neil sold HAE stock worth over $57,255.
Neil has made over 2 trades of the Haemonetics stock since 2016, according to the Form 4 filled with the SEC. Most recently Neil sold 183 units of HAE stock worth $16,970 on 7 June 2018.
The largest trade Neil's ever made was selling 964 units of Haemonetics stock on 20 October 2016 worth over $40,286. On average, Neil trades about 164 units every 85 days since 2015. As of 7 June 2018 Neil still owns at least 15,226 units of Haemonetics stock.
You can see the complete history of Neil Ryding stock trades at the bottom of the page.
Neil's mailing address filed with the SEC is 400 WOOD ROAD, , BRAINTREE, MA, 02184.
Over the last 21 years, insiders at Haemonetics have traded over $82,114,016 worth of Haemonetics stock and bought 334,931 units worth $14,646,550 . The most active insiders traders include Paul Black, Robert E Abernathy a Brad Nutter. On average, Haemonetics executives and independent directors trade stock every 13 days with the average trade being worth of $539,753. The most recent stock trade was executed by Stewart W Strong on 26 July 2024, trading 4,312 units of HAE stock currently worth $393,039.
haemonetics is the blood management company. our comprehensive portfolio of integrated devices, information management, and consulting services offers blood management solutions for each facet of the blood management continuum. collectively they help improve patient care, ensure patient safety, and reduce costs for blood and plasma collectors, hospitals, and patients around the world. our mission we believe that through proper blood management, our products and services can help our commercial plasma and blood center customers optimize their collection processes. we seek to help ensure a continual supply of high-quality plasma for biopharmaceuticals and blood components for therapeutic use at optimal costs, along with better blood management processes. working with our hospital customers, we seek to prevent a blood transfusion to the patient who doesn’t need one, or, if a transfusion is necessary, to ensure the transfusion of the right blood product, at the right time, in the right
Haemonetics executives and other stock owners filed with the SEC include: